Fabry disease and COVID-19: international expert recommendations for management based on real-world experience
Open Access
- 24 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 13 (6) , 913-925
Abstract
The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has raised questions about Fabry disease (FD) as an independent risk factor for severe COVID-19 symptoms. Available real-world data on 22 patients from an international group of healthcare providers reveals that most patients with FD experience mild-to-moderate COVID-19 symptoms with an additional complication of Fabry pain crises and transient worsening of kidney function in some cases; however, two patients over the age of 55 years with renal or cardiac disease experienced critical COVID-19 complications. These outcomes support the theory that pre-existent tissue injury and inflammation may predispose patients with more advanced FD to a more severe course of COVID-19, while less advanced FD patients do not appear to be more susceptible than the general population. Given these observed risk factors, it is best to reinforce all recommended safety precautions for individuals with advanced FD. Diagnosis of FD should not preclude providing full therapeutic and organ support as needed for patients with FD and severe or critical COVID-19, although a FD-specific safety profile review should always be conducted prior to initiating COVID-19-specific therapies. Continued specific FD therapy with enzyme replacement therapy, chaperone therapy, dialysis, renin–angiotensin blockers or participation to clinical trials during the pandemic is recommended as FD progression will only increase susceptibility to infection. In order to compile outcome data and inform best practices, an international registry for patients affected by Fabry and infected by COVID-19 should be established.Keywords
Funding Information
- FIS/FEDER (PI19/00815, DTS18/00032, ERA-PerMed-JTC2018)
- KIDNEY ATTACK (AC18/00064)
- PERSTIGAN (AC18/00071, ISCIII-RETIC)
- REDINREN (RD016/0009)
- Sociedad Española de Nefrología
- FRIAT
- Comunidad de Madrid en Biomedicina (B2017/BMD-3686)
- French ‘Plan National Maladies Rares’
This publication has 88 references indexed in Scilit:
- Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry DiseasePLOS ONE, 2011
- Social‐adaptive and psychological functioning of patients affected by Fabry diseaseJournal of Inherited Metabolic Disease, 2010
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sitesProceedings of the National Academy of Sciences of the United States of America, 2009
- Natural history of the respiratory involvement in Anderson–Fabry diseaseJournal of Inherited Metabolic Disease, 2007
- Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome surveyEuropean Heart Journal, 2007
- Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalitiesProceedings of the National Academy of Sciences, 2007
- Angiotensin-Converting Enzyme II in the Heart and the KidneyCirculation Research, 2006
- Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry DiseaseThe American Journal of Cardiology, 2005
- Signals for Sorting of Transmembrane Proteins to Endosomes and LysosomesAnnual Review of Biochemistry, 2003